Boston Scientific EKOS System Outperforms Standard Care in Pulmonary Embolism Treatment: HI-PEITHO Trial Results
ByAinvest
Saturday, Mar 28, 2026 2:24 pm ET1min read
BSX--
Boston Scientific's EKOS Endovascular System showed superiority in treating acute pulmonary embolism in a global randomized clinical trial. The study demonstrated that the EKOS system plus anticoagulation was superior to anticoagulation alone for patients with intermediate-risk pulmonary embolism. The EKOS system delivers clot-dissolving medication directly to the blood clot and uses ultrasound energy to facilitate dispersion into the clot.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet